Subsequent treatment after abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial.


Chi K. N. , Namphuong Tran N. T. , Feyerabend S., Matsubara N., Ozguroglu M. , Fein L. E.

JOURNAL OF CLINICAL ONCOLOGY, cilt.36, sa.15, 2018 (SCI İndekslerine Giren Dergi) identifier

  • Yayın Türü: Makale / Özet
  • Cilt numarası: 36 Konu: 15
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1200/jco.2018.36.15_suppl.5028
  • Dergi Adı: JOURNAL OF CLINICAL ONCOLOGY